Will new biologics stoke up competition in the targeted asthma treatment landscape?
Recent years have witnessed a rapid expansion in targeted treatments for severe asthma, and the landscape continues to evolve. Near term market dynamics will be driven by new data, delivery systems and expanded indications for Xolair, Nucala, Cinqair/Cinqaero and Fasenra. Dupixent, which recently secured US approval, could also represent a formidable competitor to the anti-IL5 mAbs. Looking further ahead, KOLs comment on how late-stage pipeline biologics tezepelumab and fevipiprant could shape the treatment algorithm, and they rate the potential of early-stage pipeline candidates targeting the IL-33/ST2 axis and IL-17.
Learn how the world’s leading asthma KOLs see the market evolving, how current products can protect market share, and how developers can differentiate their pipeline therapies in Therapy Trends KOL Insight: Targeted Therapies in Asthma. Ten North American and European KOLs provide candid insight on 5 marketed products and 7 pipeline programmes.
Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!
“Pathways and patient profiles are going to be key. For all these companies, it's going to be extremely important where their drug is going to be used and what type of patient, first line, second line. So, very much like in oncology.”
European Key Opinion Leader
“Maybe tezepelumab and anti-IL33 interference might eventually, in some patients, even cure asthma. Maybe we can administer some of these new compounds at a lower dose to patients with mild asthma in order to potentially cure them or at least keep them symptom-free for a much longer period of time.”
European Key Opinion Leader
“I certainly switch patients to the anti-IL5s, especially if they continue to have exacerbations and if they have eosinophil levels which are a good marker for responsiveness to anti-IL5 therapy. The randomised controlled data for exacerbation reduction is much stronger than for omalizumab.”
European Key Opinion Leader
Marketed/Registered Therapies
Pipeline Therapies
KOLs from North America
KOLs from Europe
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved